Pharmacological characterization and preclinical evaluation of 11h: a novel, brain-penetrant PDE4 inhibitor for neurological disorders
These findings suggest that 11h provides broad PDE4 inhibition with a favorable tolerability and pharmacokinetic profile relative to approved PDE4 inhibitors, supporting its further development as a therapeutic candidate for CNS disorders characterized by neuroinflammation.
Authors
- Atul Varadhachary
- Jacob Lackovic
- Sougata Dey
- Sara Jane Ward
- Uksha Saini
- David Tweedie
- Nigel H. Greig
- Dev Chatterjee
- Nassim Beiranvand
Institutions
- Texas Medical Center (US)
- Feminist Archive North (GB)
- South Texas Accelerated Research Therapeutics (US)
- National Institute on Aging (US)
- Io Therapeutics (United States) (US)
- Temple University (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.3389/fphar.2025.1720327
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pharmaron